Wells Fargo & Company MN Sells 172 Shares of La Jolla Pharmaceutical Company (LJPC)

Wells Fargo & Company MN decreased its position in shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) by 1.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,770 shares of the biopharmaceutical company’s stock after selling 172 shares during the period. Wells Fargo & Company MN owned 0.08% of La Jolla Pharmaceutical Company worth $410,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in LJPC. Teachers Advisors LLC raised its stake in shares of La Jolla Pharmaceutical Company by 12.4% in the fourth quarter. Teachers Advisors LLC now owns 25,390 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 2,791 shares during the last quarter. State Street Corp raised its stake in shares of La Jolla Pharmaceutical Company by 6.3% in the fourth quarter. State Street Corp now owns 227,561 shares of the biopharmaceutical company’s stock worth $3,992,000 after buying an additional 13,495 shares during the last quarter. Creative Planning purchased a new stake in shares of La Jolla Pharmaceutical Company during the first quarter worth approximately $288,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of La Jolla Pharmaceutical Company during the first quarter worth approximately $483,000.

La Jolla Pharmaceutical Company (NASDAQ LJPC) opened at 32.88 on Friday. La Jolla Pharmaceutical Company has a 1-year low of $14.63 and a 1-year high of $39.28. The company has a 50 day moving average price of $29.29 and a 200-day moving average price of $26.14. The firm’s market capitalization is $727.40 million.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.34) by $0.08. La Jolla Pharmaceutical Company had a negative return on equity of 89.72% and a negative net margin of 12,692.37%. On average, analysts forecast that La Jolla Pharmaceutical Company will post ($4.89) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://sportsperspectives.com/2017/07/15/wells-fargo-company-mn-sells-172-shares-of-la-jolla-pharmaceutical-company-ljpc.html.

A number of research firms recently commented on LJPC. ValuEngine raised La Jolla Pharmaceutical Company from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research raised La Jolla Pharmaceutical Company from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. Cowen and Company reaffirmed a “buy” rating and issued a $55.00 price objective on shares of La Jolla Pharmaceutical Company in a research note on Friday, April 28th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $57.00 price objective on shares of La Jolla Pharmaceutical Company in a research note on Monday, May 22nd. Finally, Chardan Capital set a $34.00 price objective on La Jolla Pharmaceutical Company and gave the stock a “buy” rating in a research note on Monday, May 22nd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. La Jolla Pharmaceutical Company presently has a consensus rating of “Buy” and an average price target of $43.17.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Institutional Ownership by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply